Alan McCord

Some studies have suggested a possible link between using some types of anti-depressant medications to a heightened risk of cancer. There is also evidence that certain anti-depressants might lower the risk of some cancers. Understanding the possible link between anti-depressants and cancer is particularly important for people wit HIV, because they experience higher rates of cancer than the general population, and they have a high rate of anti-depressant use.

In an abstract presented at the International AIDS Conference, antidepressants were found to not increase this risk. This large study followed 10,997 individuals at an HIV center both before and during the era of highly active antiretroviral therapy (HAART). A total of 2,004 were prescribed anti-depressants while 1,607 individuals were diagnosed with cancer during the time covered by this study. It examined the changes in the incidence of cancers based on how long they were taking antidepressants.

An analysis established the risk of both AIDS and non-AIDS cancers. This was done for each class of anti-depressants: SSRIs (selective serotonin reuptake inhibitors), TCAs (tricyclic anti-depressants), and other drugs for depression. The study examined data from the time that the individuals were exposed to antidepressants, before and during the era of HAART.

The results showed that there were no significant connections between any class of anti-depressant and any type of cancer, which included SSRIs not altering the risk of Burkitt’s lymphoma. This held true for individuals both before and during HAART. Thankfully, due to the number of scripts that are currently written, anti-depressants do not affect cancer risk in people living with HIV.

080901
PI080913

©2008. This document is copyrighted by Project Inform, 205 13th Street, #2001, San Francisco, CA 94103. Treatment Hotline: 800-822-7422 (toll-free) or 415-558-9051 (in the San Francisco Bay Area and internationally) All Project Inform materials September be reprinted and/or distributed without prior permission. However, reprints September not be edited and must include the following text: "From Project Inform, for more information contact the Project Inform National HIV/AIDS Treatment Hotline, 800-822-7422." For permission to edit any Project Inform material for further publication, contact David Evans at the Project Inform office.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1985, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS , or the party credited as the provider of the content.